Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis

AIDS

Volumn 28, Issue SUPPL. 2, 2014, Pages

  Ford, Nathan ^a   Mofenson, Lynne ^b   Shubber, Zara ^c   Calmy, Alexandra ^d,e   Andrieux Meyer, Isabelle ^e   Vitoria, Marco ^a   Shaffer, Nathan ^a   Renaud, Françoise ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

birth defects; congenital anomalies; efavirenz; HIV AIDS; pregnancy; systematic review; WHO

Indexed keywords

EFAVIRENZ; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CENTRAL NERVOUS SYSTEM MALFORMATION; COCHRANE LIBRARY; CONGENITAL MALFORMATION; DRUG SAFETY; EMBASE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; NEURAL TUBE DEFECT; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION; ABNORMALITIES, DRUG-INDUCED; CENTRAL NERVOUS SYSTEM DISEASES; CHEMICALLY INDUCED; FEMALE; HIV INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

ABNORMALITIES, DRUG-INDUCED; BENZOXAZINES; CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, FIRST; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84901433926     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000231     Document Type: Review

References (52)

1. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.Nih.Gov/ contentfiles/adultan dadolescentgl.pdf. [Accessed 26 January 2014]
2. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. HIV Med 2012; 13 (Suppl 2):1-85.
3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2013, www.who.int/hiv/pub/guidelines/arv2013. [Accessed 26 January 2014]
4. Fundarò C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16:299-300.
5. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162:355.
6. Anon. Important change in SUSTIVA (efavirenz) package insert-change from pregnancy category C to D. March 2005. http://www.fda.gov/downloads/Safety/ MedWatch/Safety Information/SafetyAlertsforHumanMedicalProducts/UCM164871. pdf. [Accessed 5 November 2013]
7. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25:2301-2304.
8. Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, Calmy A. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010; 24:1461-1470.
9. World Health Organization. Technical update on treatment optimization: use of efavirenz during pregnancy: a public health perspective. Geneva: World Health Organization; June 2012. http://apps.who.int/iris/bitstream/10665/70920/ 1/9789241503792-eng.pdf. [Accessed 14 January 2014]
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
11. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926.
12. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2013. Wilmington, NC.
13. Freeman M, Tukey J. Transformations related to the angular and the square root. Ann Inst Stat Mathematics 1950; 21:607-611.
14. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2:121-145.
15. Miller J. The inverse of the freeman-tukey double arcsine transformation. Am Stat 1978; 32:138.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
19. Knapp KM, Brogly SB, Muenz DG, Spiegel HM, Conway DH, Scott GB, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012; 31:164-170.
20. Shanske AL. Bilateral oblique facial clefts and extremity anomaly in an infant after intrauterine efavirenz exposure and review of its teratogenic risk. AIDS 2012; 26:1775-1779.
21. Floridia M, Mastroiacovo P, Tamburrini E, Tibaldi C, Todros T, Crepaldi A, et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 2013; 120:1466-1476.
22. Floridia M, Tamburrini E, Ravizza M, Anzidei G, Tibaldi C, Bucceri A, et al. Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther 2006; 11:941-946.
23. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2011. Wilmington, NC.
24. Schwartz S, Taha TE, Venter WD, Mehta S, Rees H, Black V. Efavirenz conceptions and regimen management in a prospective cohort of women on antiretroviral therapy. Infect Dis Obstet Gynecol 2012; 2012:723096.
25. Sibiude JEA. Birth defects and ART in the French perinatal cohort, a prospective exhaustive study among 13,124 live births from 1994 to 2010 [Abstract 81]. 20th Conference on Retroviruses and Opportunistic Infections; 2012; Atlanta, GA.
26. Areechokchai D, Bowonwatanuwong C, Phonrat B, Pitisuttithum P, Maek ANW. Pregnancy outcomes among HIV-infected women undergoing antiretroviral therapy. Open AIDS J 2009; 3:8-13.
27. Batallan AMG, Levine M, Longuet P, Bodard M, Legac S, et al. In utero exposure to efavirenz: evaluation in children born alive [Abstract 1100]. 2nd IAS Conference on HIV Pathogenesis and Treatment; 13-16 July 2003; Paris, France.
28. Bera E, McCausland K, Nonkwelo R, Mgudlwa B, Chacko S, Majeke B. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional south african hospital. AIDS 2010; 24:283-289.
29. Blood E, Beckwith C, Bazerman L, Cu-Uvin S, Mitty J. Pregnancy among HIV-infected refugees in rhode island. AIDS Care 2009; 21:207-211.
30. Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, Thomas AM, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in botswana. J Acquir Immune Defic Syndr 2007; 45:269-273.
31. Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012; 59:245-252.
32. Ekouevi DK, Coffie PA, Ouattara E, Moh R, Amani-Bosse C, Messou E, et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2011; 56:183-187.
33. Gonzalez-Tome MF-IM, Ramos Amador J, MunozGalligo E, Rojo C, Nieto O, et al. The Spanish cohort of HIV-infected mother-infant pairs. Efavirenz in pregnancy:, maternal characteristics of women who become pregnant on EFV-containing regimen and neonatal effects [Abstract CDB0207]. XVII International AIDS Conference, 3-8 August 2008; Mexico City, Mexico.
34. Jeantils V, Khuong MA, Delassus JL, Honore P, Taverne B, Uzan M, Tassi S. [Efavirenz (sustiva) in pregnancy: a study about 12 HIV patients]. Gynecol Obstet Fertil 2006; 34:593-596.
35. Joao ECG, Cunha C, Menezes J, Martins E, Medeiros A, et al. Pregnancy outcome in women exposed to efavirenz [Abstract CDB0698]. XVI International AIDS Conference; 13-18 August 2006; Toronto, ON.
36. Laher FFJ, Mohapi L, Gray G. Efavirenz conceptions in Soweto, South Africa [Abstract TUPEC047]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa.
37. Machado ES, Hofer CB, Costa TT, Nogueira SA, Oliveira RH, Abreu TF, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85:82-87.
38. Patel D, Thorne C, Fiore S, Newell ML. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 2005; 40:116-118.
39. Phanuphak NTS, Chinmahun A, Ooprasithiwong J, Mathajittiphun P, Jittarach K, Pima W, et al. Efficacy and safety of maternal triple-drug ARV regimens: Thai Red Cross PMTCT Program, 2004 to 2010 [Abstract 742]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, MA.
40. Rossouw T. Quantifying antiretroviral risk in pregnancy. S Afr Med J 2007; 97:1014.
41. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009; 23:519-524.
42. Westreich DRD, MacDonald P, Majuba P, Maskew M, Nagar S, Jaffray I, et al. Pregnancy, efavirenz, and birth outcomes in Johannesburg [Abstract 922]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, CA.
43. Oliveira M. Pharmacovigilance of antiretrovirals drugs in carrying pregnant women of HIV and children displayed to the HIV during the gestation in use of prophylaxis of the vertical transmission: study incidence pilot [Masters thesis]. University of Rio de Janeiro, Rio de Janeiro; 2007. 123 pp.
44. Joao ECG, Sidi L, Cruz L, Cardoso C, Cunha C, et al. Increased incidence of spontaneous abortion during first trimester exposure to efavirenz [Abstract TUPEB113]. 4th IAS Conference on HIV, Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia.
45. Taylor GT, Clayden P, Dhar J, Gandhi K, Gilleece Y, Harding K, et al. BHIVA guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012; 13 (Suppl 2):87-157.
46. European AIDS Clinical Society Guidelines. Version 7.0. October 2013. European surveillance of congenital anomalies. http://www.Eurocat-network.Eu/ accessprevalencedata/prevalence tables. [Accessed 21 February 2014]
47. Global report on birth defects. New York: March of Dimes Birth Defects Foundation White Plains; 2006. http://www.Marchof dimes.Com/glue/files/ birthdefectsexecutivesummary.pdf.
48. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343:d4002.
49. Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note of caution. J Infect Dis 2012; 206:1639-1641.
50. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097S). HIV Clin Trials 2009; 10:343-355.
51. Journot V, Chene G, De Castro N, Rancinan C, Cassuto JP, Allard C, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial alize-anrs 099. Clin Infect Dis 2006; 42:1790-1799.
52. World Health Organization. Toxicity surveillance of antiretroviral drugs in pregnancy and breastfeeding. Geneva: World Health Organization. http://www.who.int/hiv/topics/arv-toxi city/en/index.html. [Accessed 21 February 2014]